



INSTITUTE OF EXPERIMENTAL MEDICINE

FACULTY OF MEDICINE

PAVOL JOZEF ŠAFÁRIK UNIVERSITY IN KOŠICE



Alojz Bomba







THE MAIN OBJECTIVE OF THE CONCEPT OF THE INSTITUTE'S ACTIVITIES

- Building the research institute of the highest international level focusing on research in the prevention and treatment of chronic diseases
- Application of interdisciplinary approach and teamwork
- Engagement of the Institute into international consortia of research projects in the European Union Framework Programme for Research and Innovation Horizon 2020





RESEARCH TEAM



GROUP LEADER: Alojz BOMBA, DVM, DSc

- 6 senior scientists
- 5 junior scientist
- 3 PhD students
- 3 technicians



LONG-TERM RESEARCH PROGRAM

The role of gut microbiota in pathogenesis of chronic diseases and possibilities of targeted modulation and transplantation of gut microbiota in chronic disease prevention and treatment





INFRASTRUCTURE



Molecular biology Lab



Microbiology Lab



Cell culture Lab



Biochemistry Lab




Mass Spectrometry Lab



Immunology Lab




EXPERIMENTAL MODELS





SHIME [®] SIMULATOR OF THE HUMAN INTESTINAL MICROBIAL ECOLOGY


ProDigest







RESEARCH




- What is the role of gut microbiome in health and pathogenesis of chronic diseases?
- What are possibilities for prevention and treatment of chronic diseases using targeted modulation and transplantation of gut microbiota?






THE COMPOSITION OF GUT MICROBIOTA




THE COMPOSITION OF GUT MICROBIOTA DEPENDING ON AGE

IEM INSTITUTE OF EXPERIMENTAL MEDICINE






GUT MICROBIOTA IN HEALTH AND DISEASE




GUT MICROBIOTA, INFLAMMATION AND METABOLISM





GUT MICROBIOTA IN HEALTH AND DISEASE

- Better understanding of the bacterial communities inhabiting human gut and properties of healthy microbiota
- The role of dysbiosis in various disease states
- New therapeutics in the treatment of diseases using microbiota





DEFINITION OF PROBIOTICS

Live microorganisms which when administered in adequate amounts confer a health benefit on the host

(FAO and WHO 2001)

Lactobacilli (Lactobacillus casei, L.acidophilus, L.lactis, L.plantarum)



Bifidobacteria (Bifidobacterium bifidum)



BIOMEDICAL EFFECTS OF PROBIOTICS








MODULATION OF LIPID METABOLISM BY PROBIOTICS IN HIGH-FAT DIET FED RATS

Total serum cholesterol concentration in rats fed by high fat diet




C: Control group; HFD: high fat diet; LPS: HFD + *L. plantarum* LS/07 LPP: HFD + *L. plantarum* LP96 The values with different superscript letters differ significantly (p< 0.05)

Salaj, R. et al., 2013



MODULATION OF GUT MICROBIOTA IN PREVENTION OF ACUTE COLITIS USING PROBIOTICS

Efectt of *L. plantarum* application on gut morphology of rats in chemically induced acute colitis (DSS)




Control group

DSS group (colitis)

L. plantarum group




POTENTIATED PROBIOTICS



THE EFFECT OF N-3 POLYUNSATURATED FATTY ACIDS ON THE INHIBITORY EFFECT OF LACTOBACILLUS PLANTARUM ON THE ADHERENCE OF E. COLI O8:K88AB:H9 IN THE GUT OF GNOTOBIOTIC PIGLETS SUPPLEMENTED WITH FLAX-SEED OIL


The counts of *Lactobacillus plantarum* adhering to the intestinal mucosa of 9-day-old gnotobiotic pigs after administration of flax-seed oil




Nemcová et al., 2012

THE EFFECT OF LACTOBACILLUS PLANTARUM AND N-3 POLYUNSATURATED FATTY ACIDS (PUFA) ON TOTAL CHOLESTEROL SERUM CONCENTRATION IN RATS

Total serum cholesterol concentration (mmol/l)



THE EFFECT OF *LACTOBACILLUS PLANTARUM* (PRO) AND N-3 POLYUNSATURATED FATTY ACIDS (PUFA) ON ACTIVITY OF BACTERIAL ENZYMES IN 1,2-DIMETHYLHYDRAZINE EXPOSED RATS



β-glucuronidase activity

sign. different from DMH *** (p<0,001)

Strojný et al., 2011



AUTOPROBIOTICS

Autoprobiotic technology is based on the indigenous bacteria used for restoring the normal microbiota in the case of a dysbiotic condition













ADMINISTRATION OF DEFINED MICROBIOTA Stool substitute transplant therapy

It was demonstrated that a stool substitute mixture comprising a multi-species community of bacteria is capable of curing antibiotic-resistant *C. difficile* colitis






FECAL MICROBIOTA TRANSPLANTATION



With Personalized Medicine:

Each Patient Receives the Right Medicine For Them





TARGETED MODULATION OF GUT MICROBIOTA IN DISEASE PREVENTION AND TREATMENT

- Original solution of gut microbiota modulation which could possibly meet criteria of the personalized medicine approach
- Our solution eliminates the risks connected with the fecal microbiota transplantation from donor and it allows the targeted modulation according to specific needs of the patient





PERSPECTIVES

- The completion of a top international level research institute
- New, original and effective solution of targeted gut microbiota modulation in chronic disease prevention and treatment
- Participation in international consortia of research projects in European Union Framework Programme for Research and Innovation



Thank you for your attention